 on
potential adverse events such as endoleak, need for reintervention, and device failures. The committee also placed less
value on possible late-term outcomes that remain unknown
at this time. Furthermore, the committee acknowledges the
off-label use of a medical device in the context of endovascular repair of traumatic thoracic aortic injury, although
there are ongoing studies investigating the safety and efficacy in this application; however, as we believe that pre-

JOURNAL OF VASCULAR